These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 479061)

  • 1. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 2. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
    Thomsen J; Friis B
    Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 4. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract]   [Full Text] [Related]  

  • 5. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 9. [Ochrobactrum anthropi bacteremia in a child with cystic fibrosis].
    Yagüe-Muñoz A; Gregori-Roig P; Valls-López S; Pantoja-Martínez J
    Enferm Infecc Microbiol Clin; 2010 Feb; 28(2):137-8. PubMed ID: 19811858
    [No Abstract]   [Full Text] [Related]  

  • 10. [Making antibiotic therapy easier to use. A welcome advance for those with cystic fibrosis].
    Sabourin G
    Perspect Infirm; 2011; 8(4):54-5. PubMed ID: 21812190
    [No Abstract]   [Full Text] [Related]  

  • 11. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
    Pedersen SS; Jensen T; Osterhammel D; Osterhammel P
    Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB; Rosenstein BJ
    Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pseudomonas infections in lungs of children born with cystic fibrosis. Effects and adverse effects during antibiotic therapy with tobramycin and carbenicillin].
    Friis B; Thomsen J
    Ugeskr Laeger; 1979 Jul; 141(29):1968-72. PubMed ID: 545764
    [No Abstract]   [Full Text] [Related]  

  • 15. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Adeboyeku D; Jones AL; Hodson ME
    J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
    Conway SP; Miller MG; Ramsden C; Littlewood JM
    Acta Paediatr Scand; 1985 Jan; 74(1):107-13. PubMed ID: 3885674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA; Nagel JL
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.